We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pfizer, BioNTech Delay Seeking COVID-19 Vaccine Authorization in Children Under Five

Pfizer, BioNTech Delay Seeking COVID-19 Vaccine Authorization in Children Under Five

February 14, 2022

Pfizer and BioNTech announced Friday that they will hold off pursuing an expanded FDA Emergency Use Authorization (EUA) permitting use of their COVID-19 vaccine in children under age five, in order to gather more data on whether a third booster dose is needed.

That same day, the FDA said it will postpone a scheduled meeting of its Vaccines and Related Biological Products Advisory Committee, originally slated for Tuesday to review the expanded EUA application. Instead, the agency will reschedule the expert panel review after receiving the additional data from Pfizer and BioNTech.

“The trial in children six months through four years of age is ongoing and data on the first two 3- µg doses in this age group are being shared with the FDA on an ongoing basis,” said the companies, explaining that more data are being generated because rates of infection and illness remain high in children of this age, especially due to the recent Omicron surge.

Meanwhile, Acting FDA Commissioner Janet Woodcock and Peter Marks, director of the agency’s Center for Biologics Evaluation and Research, said in a joint statement that being “able to begin evaluating initial data has been useful in our review of these vaccines, but at this time, we believe additional information regarding the ongoing evaluation of a third dose should be considered.”

Earlier this month, Pfizer and BioNTech had sought an updated EUA that would allow a two-dose COVID-19 vaccine regimen in children six months to four years old, submitting data from a phase 1/2/3 trial of 8.300 children aged six months to 12 years to support their application. However, at the time, the companies noted they were still waiting on further trial data to decide whether to add a third dose to the expanded EUA request (DID, Feb. 2).

And the companies are also assessing the effectiveness of a third 10-µg booster dose in children aged five to 11 years old. The drugmakers previously won an expanded authorization allowing a two-dose vaccine regimen for this age group in late October (DID, Nov. 1, 2021).

The companies have already received full approval for the vaccine in adults and EUAs for adolescents and preteens. — Jason Scott

COVID-19

Upcoming Events

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 27Jul

    Applying the Lessons of the Pandemic to Your Upcoming Trial

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Warns Baby Neck Floats Used in Water Therapy Can Cause Death or Injury

  • U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

  • FX Receives FDA Clearance for Its FX V135 Shoulder Arthroplasty Platform

  • FDA Recommends Modified COVID-19 Vaccine Boosters Adapted to Omicron BA.4 and BA.5 Subvariants

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing